SCHEMBL498603

SCHEMBL498603

Brc1ccc(-c2ccc(-c3cccs3)s2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.53
LTA4H P09960 1/20 0.50
HDAC1 Q13547 1/20 0.50
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 7/20 0.47
L3MBTL1 Q9Y468 5/20 0.47
MAPT P10636 4/20 0.47
GAA P10253 3/20 0.47
LMNA P02545 2/20 0.47
GLA P06280 2/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196515 0.98 LTA4H (0.52) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL1105086 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL14703073 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL15957843 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL2742433 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL23611278 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL13707354 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
Alpha-Terthienyl SCHEMBL147274 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL499333 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E
SCHEMBL13707359 0.86 DPP4 (0.65) DPP4LTA4HHDAC1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202954-B2 Rubber composition and crosslinked rubber molded product SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2025-01-21 US disclosed
US-20230114853-A1 RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2023-04-13 US disclosed
US-20220081305-A1 CRYSTAL, METHOD OF PRODUCING CRYSTAL, AND METHOD OF SELF-ORGANIZING SILANOL COMPOUND NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2022-03-17 US disclosed
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 EP disclosed
US-20170267814-A1 Controlled Radical Polymerization, and Catalysts Useful Therein BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2017-09-21 US disclosed
US-9644072-B2 Controlled radical polymerization, and catalysts useful therein BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2017-05-09 US disclosed
US-9226917-B2 Photodynamic therapy for conditions of the eye VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2016-01-05 US disclosed
EP-2479160-B1 PROCESS FOR PRODUCTION OF OXIDATION REACTION PRODUCT OF AROMATIC COMPOUND UNIV OSAKA (JP) 2015-09-09 EP disclosed
US-8968715-B2 Drug delivery systems for photodynamic therapy THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-03-03 US disclosed
US-8852629-B2 Drug delivery system for hydrophobic drugs VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2014-10-07 US disclosed
WO-2002062386-A2 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QLT INC. (CA) 2002-08-15 WO disclosed
EP-1229937-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT Inc. (CA) 2002-08-14 EP disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed
WO-2001035997-A2 USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS QLT INC. (CA) 2001-05-25 WO disclosed
US-5753692-A PLANT EXTRACTS, IMMUNOSTIMULANTS TREATING IMMUNODEFICIENCY DISEASES INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1998-05-19 US disclosed
US-5747525-A ANTITUMOR AGENTS OF OLIGOMERS OF THIOPHENE INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1998-05-05 US disclosed
US-5602170-A ADMINISTERING ANTIIFLAMMATORY AGENT INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1997-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA DPP4 2865/4885LTA4H 1099/4885HDAC1 2845/4885
US-20170267814-A1 Controlled Radical Polymerization, and Catalysts Useful Therein SOD1, PCNA, CLTB DPP4 4656/4885LTA4H 3744/4885HDAC1 1398/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 DPP4 1489/4885LTA4H 846/4885HDAC1 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.